All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On 3 December 2018, during the 60th Annual Meeting of the American Society of Hematology (ASH), San Diego, CA, Arnon Kater from the University of Amsterdam, Amsterdam, NL, presented an updated analysis from the MURANO phase III trial (Abstract #695).
This abstract was presented during Oral Session 642 ‘CLL: Therapy, excluding Transplantation: Advances in CLL Using Novel Combination Therapy’ and provided the first prospective data on the impact of minimal residual disease (MRD) on long-term patient outcomes following the MURANO phase III trial. The MURANO trial demonstrated that fixed-duration venetoclax and rituximab (VenR) provide a significantly longer progression-free survival (PFS), compared to bendamustine and rituximab (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients. Here, peripheral blood (PB) MRD analysis related to long-term PFS outcomes from the MURANO study was performed.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox